SC
RARE icon

Samlyn Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Samlyn Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-55,000
Closed -$3.87M – 163
2016
Q4 		$3.87M Buy
+55,000
New +$3.9M 0.09% 112

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Samlyn Capital's RARE Position: Q1 2017 in Review

Samlyn Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 55,000 shares — an estimated $3.87M sold.

Samlyn Capital first reported a position in RARE in Q4 2016 and held it in 1 quarter. The position peaked at $3.87M in Q4 2016. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

  • Samlyn Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
  • Samlyn Capital sold 55,000 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $3.87M.
  • Samlyn Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 1 quarter.
  • Samlyn Capital's Ultragenyx Pharmaceutical position peaked at $3.87M in Q4 2016.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Samlyn Capital's 13F filing for Q1 2017, filed 15 May 2017.